Journal
IMMUNOLOGY AND CELL BIOLOGY
Volume 87, Issue 8, Pages 634-639Publisher
WILEY
DOI: 10.1038/icb.2009.53
Keywords
adenosine deaminase; anti-HIV response; cytokines as vaccine adjuvant; T-cell proliferation; dendritic cells
Categories
Funding
- Fundacio Marato of Catalonian Telethon [02/021010, FIPSE 36750/08]
Ask authors/readers for more resources
As host immunological defenses are impaired during HIV infection, it is difficult to elicit good responses when attempting to develop therapeutic vaccines against HIV. To try to solve this situation, adjuvants, particularly cytokines, are currently under evaluation. Owing to the fact that adenosine deaminase (ADA) is a member of the family of growth factor with deaminase activity, we tested whether it could improve immune responses in the development of HIV dendritic-cell-based therapeutic vaccines. A co-culture model approach has been used to test the usefulness of ADA as adjuvant. Monocyte-derived dendritic cells from HIV-infected patients were pulsed with inactivated HIV, matured and co-cultured with autologous T cells. Addition of ADA to the co-cultures resulted in enhanced CD4(+) and CD8(+) T-cell proliferation and robust ADA-induced increase in cytokine production (IFN-gamma, TNF-alpha and IL-6). As IFN-gamma, TNF-alpha and IL-6 promote the Th1 versus Th2 phenotype and improve T helper proliferation responses and antigen-specific CTL responses ADA may be considered a promising candidate for therapeutic vaccine adjuvant. Immunology and Cell Biology (2009) 87, 634-639; doi: 10.1038/icb.2009.53; published online 11 August 2009
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available